Article
Biochemistry & Molecular Biology
Philipp Georg, Rosario Astaburuaga-Garcia, Lorenzo Bonaguro, Sophia Brumhard, Laura Michalick, Lena J. Lippert, Tomislav Kostevc, Christiane Gaebel, Maria Schneider, Mathias Streitz, Vadim Demichev, Ioanna Gemuend, Matthias Barone, Pinkus Tober-Lau, Elisa T. Helbig, David Hillus, Lev Petrov, Julia Stein, Hannah-Philine Dey, Daniela Paclik, Christina Iwert, Michael Muelleder, Simran Kaur Aulakh, Sonja Djudjaj, Roman D. Buelow, Henrik E. Mei, Axel R. Schulz, Andreas Thiel, Stefan Hippenstiel, Antoine-Emmanuel Saliba, Roland Eils, Irina Lehmann, Marcus A. Mall, Sebastian Stricker, Jobst Roehmel, Victor M. Corman, Dieter Beule, Emanuel Wyler, Markus Landthaler, Benedikt Obermayer, Saskia von Stillfried, Peter Boor, Munevver Demir, Hans Wesselmann, Norbert Suttorp, Alexander Uhrig, Holger Mueller-Redetzky, Jacob Nattermann, Wolfgang M. Kuebler, Christian Meisel, Markus Ralser, Joachim L. Schultze, Anna C. Aschenbrenner, Charlotte Thibeault, Florian Kurth, Leif E. Sander, Nils Bluethgen, Birgit Sawitzki
Summary: Severe COVID-19 is associated with highly activated CD16(+) T cells that exhibit cytotoxic functions and contribute to endothelial injury. These CD16(+) T cells can degranulate and induce cytotoxicity through immune-complex-mediated mechanisms independent of the T cell receptor, which is not observed in other diseases. The presence of activated CD16(+) T cells and elevated levels of complement proteins upstream of C3a are associated with a fatal outcome of COVID-19, indicating the pathological role of enhanced cytotoxicity and complement activation in the disease.
Article
Immunology
Lore Billiet, Laurenz De Cock, Guillem Sanchez Sanchez, Rupert L. Mayer, Glenn Goetgeluk, Stijn De Munter, Melissa Pille, Joline Ingels, Hanne Jansen, Karin Weening, Eva Pascal, Killian Raes, Sarah Bonte, Tessa Kerre, Niels Vandamme, Ruth Seurinck, Jana Roels, Marieke Lavaert, Filip Van Nieuwerburgh, Georges Leclercq, Tom Taghon, Francis Impens, Bjorn Menten, David Vermijlen, Bart Vandekerckhove
Summary: Billiet et al. identify a well-defined but heterogeneous unconventional TCR alpha beta(+) lineage mainly confined to CD8(+) Helios(+) T cells, which represents the post-thymic progeny of CD10(+) PD-1(+) precursors in humans. These unconventional T cells (UTCs) in thymus and blood share a common developmental trajectory, characterized by hallmark transcription factors (ZNF683 and IKZF2) and a polycolonal TCR repertoire with autoreactive features. The UTC lineage can be identified in adult blood and intestinal tissues.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Review
Oncology
Rahul S. Bhansali, Stefan K. Barta
Summary: Mature T- and NK-cell neoplasms are a heterogeneous group of diseases that account for approximately 15% of non-Hodgkin lymphomas. Central nervous system progression/relapse is a devastating outcome for these patients, but there are no established standards of care for its prophylaxis and treatment due to the infrequency and heterogeneity of tumor biology. This review discusses the epidemiology, risk factors, and potential strategies for prophylaxis and therapy in patients with mature T- and NK-cell lymphomas.
Article
Health Care Sciences & Services
Mathew G. Angelos, Hatcher J. Ballard, Stefan K. Barta
Summary: Peripheral T-cell lymphomas (PTCLs) are a rare and aggressive subset of lymphomas with poor response to traditional chemotherapy, but have shown improved outcomes with newer targeted therapies. FDA-approved novel agents have demonstrated superior efficacy in specific PTCL subtypes, leading to potential expansion of frontline treatment strategies.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Medicine, General & Internal
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Summary: Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that usually presents with a nasal mass. Limited disease is treated with chemotherapy and radiation, while advanced stage disease is treated with L-asparaginase containing chemotherapy regimens. Modern radiation therapy techniques and the use of L-asparaginase in chemotherapy have improved outcomes, but relapse and relapse-related deaths remain frequent. Novel therapies have been evaluated for the treatment of this disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Hamid Bolouri, Rhonda Ries, Laura Pardo, Tiffany Hylkema, Wanding Zhou, Jenny L. Smith, Amanda Leonti, Michael Loken, Jason E. Farrar, Timothy J. Triche, Soheil Meshinchi
Summary: Infant Acute Myeloid Leukemia (AML) is a challenging and heterogeneous malignancy with relatively few mutations per patient but many age-specific translocations; there are more structural genomic aberrations and fewer mutations in infant AML compared to AML in older children/adults; integrative analyses of genome-wide data in diagnosis-stage patient samples showed the activation of an onco-fetal B-cell gene regulatory network in infant AML.
Article
Biotechnology & Applied Microbiology
Yang Wu, Dan Chen, Ya Lu, Shu-Chen Dong, Rong Ma, Wei-yan Tang, Jian-qiu Wu, Ji-Feng Feng, Jian-Zhong Wu
Summary: The study demonstrated an effective CAR-T cell treatment for CD30-positive PTCL tumors by using CD30 CAR T cells to suppress tumor growth.
CANCER GENE THERAPY
(2022)
Article
Immunology
Pavel Shelyakin, Ksenia R. Lupyr, Evgeny S. Egorov, Ilya A. Kofiadi, Dmitriy B. Staroverov, Sofya A. Kasatskaya, Valeriia V. Kriukova, Irina A. Shagina, Ekaterina M. Merzlyak, Tatiana O. Nakonechnaya, Elena A. Latysheva, Irina A. Manto, Musa R. Khaitov, Sergey A. Lukyanov, Dmitriy M. Chudakov, Olga Britanova
Summary: The interplay between T- and B-cell compartments during naive, effector and memory T cell maturation is critical for a balanced immune response. Primary B-cell immunodeficiency arising from X-linked agammaglobulinemia (XLA) offers a model to explore B cell impact on T cell subsets, starting from the thymic selection. The findings suggest active B cell involvement in CD4 T cell subsets maturation, including B cell-dependent expansion of the naive Treg TCR repertoire that enables better control of self-reactive T cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Chantana Polprasert, Yasuhide Takeuchi, Hideki Makishima, Kitsada Wudhikarn, Nobuyuki Kakiuchi, Nichthida Tangnuntachai, Thamathorn Assanasen, Wimonmas Sitthi, Hamidah Muhamad, Panisinee Lawasut, Sunisa Kongkiatkamon, Udomsak Bunworasate, Koji Lzutsu, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Kenichi Yoshida, Ponlapat Rojnuckarin
Summary: ENKTCLs are aggressive lymphomas predominantly affecting Asians. Defective HLA-A gene is recurrently identified in ENKTCLs and associated with disease progression, suggesting immune escape as a pathogenic mechanism.
LEUKEMIA & LYMPHOMA
(2021)
Review
Oncology
Hazim S. Ababneh, Jeremy S. Abramson, P. Connor Johnson, Chirayu G. Patel
Summary: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigm for patients with relapsed or refractory disease, with significant response rates. However, the time required for CAR T-cell therapy leaves many patients in need of bridging therapy. Radiation therapy has shown to be effective as a bridging therapy and may have synergy with CAR T-cells.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Pathology
Andrew L. Feldman, Camille Laurent, Marina Narbaitz, Shigeo Nakamura, Wing C. Chan, Laurence de Leval, Philippe Gaulard
Summary: This article discusses the classification and diagnostic evaluation of nodal T- and NK-cell lymphomas based on the 2022 International Consensus Classification of Mature Lymphoid Neoplasms (2022 ICC). It highlights the grouping of T-follicular helper cell lymphoma into a single entity with three subtypes, as well as the genetic subtype of ALK-negative anaplastic large cell lymphoma (ALCL) associated with DUSP22 rearrangement. The introduction of a new provisional entity, primary nodal EBV-positive T-/NK-cell lymphoma, is also mentioned, along with evolving molecular data indicating distinct subgroups within PTCL, NOS.
Article
Gastroenterology & Hepatology
Yi Lu, Hailing Liu, Xianhua Zhuo, Tingzhi Liu, Xiaoying Lou, Chujun Li, Min Zhi
Summary: Diagnosing and treating gastrointestinal T-cell and NK/T-cell lymphomas can be challenging, and further research is needed to improve accuracy and prognosis.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Natsumi Hara, Yu Sawada
Summary: Epigenetic modifications rarely occur alone, but rather form a network to control the epigenetic system. Limited knowledge exists about the epigenetic changes associated with cutaneous lymphomas. This review focuses on cutaneous T-cell lymphomas, summarizing the chemical modifications of DNA methylation, histone acetylation, and methylation. Current research on epigenetic-targeted therapy against cutaneous T-cell lymphomas is discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yuqin Song, Yok Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, HyeJin Kim, Min Qing, Tianyuan Zhou, Grace Gao, Zongqi Dong, Ming Qi, Won Seog Kim
Summary: In this study, daratumumab monotherapy showed an overall response rate of 25.0% in patients with relapsed or refractory NKTCL. However, no patients achieved complete response, and the duration of response was short. Adverse events were manageable and there were no new safety concerns identified.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Sushant Kumar, Bhavuk Dhamija, Diksha Attrish, Vinanti Sawant, Manju Sengar, Jayashree Thorat, Tanuja Shet, Hasmukh Jain, Rahul Purwar
Summary: T cell lymphomas are a diverse group of Non-Hodgkin lymphomas with a wide range of clinical manifestations, driven by genetic alterations and cellular processes such as T cell signaling and differentiation. Targeting genetic abnormalities and oxidative stress may lead to improved therapeutic outcomes and new combination treatments for T cell lymphomas.
PHARMACOLOGY & THERAPEUTICS
(2022)